Boehringer Ingelheim GmbH Release: Data Presented at EASD Support Safety Profile of Trajenta® (Linagliptin) In Broad Range of Adults With Type 2 Diabetes

For Non-US and Non-UK Media

Boehringer Ingelheim and Eli Lilly and Company today announced that results from two different pooled analyses of clinical studies support previous observations that the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin was shown to be well tolerated in a broad range of adults with Type 2 Diabetes (T2D). These data were presented at the 49th European Association of Diabetes (EASD) Annual Meeting.

Help employers find you! Check out all the jobs and post your resume.